Vardenafil ODT, (Staxyn, BAY38-9456)
DrugSingle dose of 10 mg of vardenafil ODT, taken without water
NCT Number: NCT01348880
The study will be conducted as a multi-center, randomized, double-blinded, placebo controlled, crossover design. The investigational drug (vardenafil ODT (Orally Disintegrating Tablet)/placebo) will be given as a single administration at a dose of 10 mg vardenafil ODT during Period 1 or 2; the blinded matching placebo will be given as a single administration during the opposing period. The random code will determine the order of active drug (vardenafil ODT) and placebo for each subject. Blood pressure and heart rate profiles will be recorded by automated device pre-dose for 8 hours post-dose during Periods 1 and 2. The non investigational drug product (vasodilator), Procardia XL, will be background treatment for hypertension, taken daily by each subject. All subjects must be stable on the vasodilator for at least 4 weeks prior to Day 1 of Period 1. Special conditions for this study include the requirement that all subjects will be male, are between the ages of 65 and 80 years, and will have a diagnosis of erectile dysfunction (ED), as well as hypertension. Planned sample size will be 40 subjects evaluable for the primary analysis. Of the 40 subjects valid for this analysis, 20 will be between the ages of 65 and 69 years, and 20 subjects will be between the ages of 70 and 80 years. The total duration of the study will be approximately one year from first subject treated to last subject treated, including replacement of any subjects who fail to complete both periods of crossover dosing.
Looking for future studies?
Notify Me65 year–80 year
Male
Interventional
Phase 1
Miami, Florida, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Subjects must fulfill all of the following criteria before being included in the treatment period i.e., before receiving any dose of the study related medication (Sponsor supplied Procardia XL, or vardenafil Orally Disintegrating Tablet (ODT) /placebo tablets):
Exclusion criteria
Subjects are to be excluded from the study if they display any of the following criteria:
Medical and surgical history
Single dose of 10 mg of vardenafil ODT, taken without water
Single dose of placebo to match 10 mg vardenafil ODT. taken without water
Time frame: Up to 8 hours of combination dosing of vardenafil ODT and nifedipine.
Time frame: Up to 8 hours of combination dosing of vardenafil ODT and nifedipine
Time frame: Up to 8 hours of combination dosing of vardenafil ODT and nifedipine
Time frame: Up to 8 hours of combination dosing of vardenafil ODT and nifedipine
Time frame: Up to 8 hours of combination dosing of vardenafil ODT and nifedipine
Time frame: Up to 8 hours of combination dosing of vardenafil ODT and nifedipine
Time frame: Up to 8 hours of combination dosing of vardenafil ODT and nifedipine
Time frame: up to end of study
Safety parameters included physical examinations, adverse events, laboratory values, electrocardiogram, concomitant medications, and vital signs
Time frame: 1 and 2 weeks prior to the Day 1 dosing of the combination of nifedipine/vardenafil as well as at Visit 4 and Visit 5
Bayer
Industry
A Double-Blind Study to Evaluate the Pharmacodynamic Interaction Between 10 mg Vardenafil ODT (Orally Disintegrating Tablet) and Procardia XL® (Nifedipine GITS) in Elderly Male Patients With Both Hypertension and Erectile Dysfunction
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07715448
Benign Prostatic Hyperplasia, Ejaculatory Dysfunction
Banī Suwayf, Beni Suef Governorate, Egypt
View Trial DetailsNCT06805513
Erectile Dysfunction, Genital Diseases
Salt Lake City, Utah, United States
View Trial DetailsNCT07692867
Erectile Dysfunction, Genital Diseases
Beijing, China
View Trial DetailsNCT07460167
Erectile Dysfunction, Genital Diseases
Qina, Egypt
View Trial Details